THE TAPE

Phibro Animal Health Corporation Class A

$35.02▼ −2.64%
Last close
Relative strength
33RS
of 99, against every stock▼ -7 on the month
Falling back
Unconfirmed
−7.8%
six months against Pharmaceutical Preparations
52-week range
−41.7%
from the high
$28.25$60.08
Setup
blue skyplayed out
−37.8%
against the pivot at $56.30
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +6% on a year ago
11/16 O 36.04 H 36.08 L 34.84 Vol 193.6K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS33
vs pivot−37.80%
Tightening0.96×
Dry-up0.99×
Up/down vol0.15
From high42%
played out1 of 9checks
Previous breakout trailed out ▲ +5.00% in Feb
Falling back
Support and resistance
Support below
$34.42
-1.7% · tested 6× · last 41 sessions ago
Resistance above
$36.01
+2.8% · tested 5× · last 23 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 6.4 weeks and fell 20% from its ceiling at its deepest. The pivot is $56.30, and the stock closed 37.8% below it. Its relative strength rating is 33.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-13.6%
Three months against its industry
+16.8%
Six months against its industry
-7.8%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap
9
days
Ex-dividend in 9 days
Nov 25, 2026
  1. Ex-dividendconfirmedin 9d
    Ex-dividend date
    Nov 25, 2026
How it moves on earnings

On average 12.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$1.5B
+6.3% year on year
Operating margin
12.5%
gross 33.8%
Net margin
6.7%
Free cash flow
$21.7M
1.5% of market cap
Price to sales
0.92×
Price to earnings
13.8×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$386.8M
-2.5% QoQ · +6.3% YoY
Gross margin
33.2%
-0.7 pts QoQ
Net income
$29.5M
Positive
Free cash flow
$7.3M
Cash generating

What the numbers say

  • Revenue +6.3% year over year, -2.5% on the quarter
  • Gross margin 33.2%, -0.7 points on the quarter
  • Good: Profitable: net income $30M, operating margin 12.8%
  • Good: Cash generating: operating cash flow $26M, free cash flow $7M
  • Net debt $535M · cash $76M
Revenue by quarter
Free cash flow
Net income
shares +0.2% in a year · net debt $535.3M

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
GappedTape · 2026-11-10
+5.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
-6.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-10.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-10.2% on earnings 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-11-03
reports 2026-11-04 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Earnings date movedEvent · 2026-10-31
2026-11-11 -> 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Earnings date movedEvent · 2026-10-21
2026-11-03 -> 2026-11-11
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
1
$317,700 total
Sold on the open market
0

Bought: CORCORAN E THOMAS.

Not counted above: 8 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-08-06 Rodriguez Patrick · VP Finance and Treasureraward1,503
2026-08-06 David Glenn · Chief Financial Officeraward3,334
2026-08-06 Miller Larry Lee · Chief Operating Officeraward3,522
2026-08-06 BENDHEIM Jonathan · Directoraward2,716
2026-08-06 Weinstein Judith · See Remarksaward2,478
2026-08-06 BENDHEIM JACK · Executive Chairman, Director, 10% owneraward12,103
2026-08-06 Escudero Lisa Ann · See Remarksaward1,547
2026-08-06 Bendheim Daniel M · President and CEO, Directoraward11,699

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

1 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy0
Hold2
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

The most recent of 4 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Phibro Animal Health Corporation Class A (PAHC) — The Tape